Your browser doesn't support javascript.
loading
Corrigendum to "Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial" [Vaccine 35 (2017) 395-402].
Iro, Mildred A; Snape, Matthew D; Voysey, Merryn; Jawad, Sena; Finn, Adam; Heath, Paul T; Bona, Gianni; Esposito, Susanna; Diez-Domingo, Javier; Prymula, Roman; Odueyungbo, Adefowope; Toneatto, Daniela; Dull, Peter; Pollard, Andrew J.
Afiliação
  • Iro MA; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK. Electronic address: mildred.iro@paediatrics.ox.ac.uk.
  • Snape MD; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
  • Voysey M; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK; Nuffield Department of Primary Health Care Health Sciences, University of Oxford, Oxford, UK.
  • Jawad S; Nuffield Department of Primary Health Care Health Sciences, University of Oxford, Oxford, UK.
  • Finn A; Bristol Children's Vaccine Centre, University of Bristol, Bristol, UK.
  • Heath PT; St Georges Vaccine Institute, St George's, University of London, London, UK.
  • Bona G; Azienda Ospedaliero-Universitaria Maggiore della Carità, Clinica Pediatrica, Novara, Italy.
  • Esposito S; Pediatric Highly Intensive Care Unit, Università degli Studi di Milano, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Diez-Domingo J; Vaccine Research Area, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Valencia, Spain.
  • Prymula R; Charles University Prague, School of Medicine Hradec Kralove, Czech Republic.
  • Odueyungbo A; Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA.
  • Toneatto D; GSK Vaccines S.r.l., Siena, Italy.
  • Dull P; Novartis Vaccines and Diagnostics Inc., Cambridge, MA, USA.
  • Pollard AJ; Oxford Vaccine Group, Department of Paediatrics, University of Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, UK.
Vaccine ; 35(24): 3279, 2017 05 31.
Article em En | MEDLINE | ID: mdl-28483197
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2017 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Ano de publicação: 2017 Tipo de documento: Article